Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure (Q36357441)

13 August 2017

1 reference

title

Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure (English)

1 reference

13 August 2017

1 reference

Lehmkuhl H

1

1 reference

13 August 2017

Ross H

series ordinal

2

1 reference

13 August 2017

Eisen H

series ordinal

3

1 reference

13 August 2017

Valantine H

series ordinal

4

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

Transplantation Proceedings

13 August 2017

1 reference

13 August 2017

37

1 reference

13 August 2017

10

1 reference

13 August 2017

4145-4149

1 reference

Cyclosporine renal dysfunction

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Cardiac allograft vasculopathy after heart transplantation: risk factors and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.10.005

10.1016/J.TRANSPROCEED.2005.10.005

7 January 2021

Identifiers

DOI

1 reference

13 August 2017

1 reference